New Treatments For Scleroderma 2025. In their new study published in jci insight, researchers found that tofacitinib was well tolerated among patients with early systemic sclerosis, and discovered the drug primarily. Despite recent groundbreaking advancements in understanding ssc pathophysiology, early diagnosis and early introduction of effective targeted treatments within the optimal window of.
Researchers find gene mutations in scleroderma patients that could point to new treatments Sanofi and boehringer ingelheim will each contribute an experimental agent to conquest, and as such they are the first pharma partners to commit to this protocol.